New treatment to help manage pain crises in sickle cell disease at home
Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease
This study is testing a new treatment called IHP-100 to help people with sickle cell disease manage their pain at home, making it easier for them to handle painful episodes without always needing to go to the hospital.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ihp Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project ID | NIH-10910229 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapeutic called IHP-100, which aims to empower patients with sickle cell disease to manage their acute pain crises at home. The treatment involves a subcutaneous injection that targets the underlying causes of vaso-occlusive crises, specifically by inhibiting P-selectin and complement activation. By addressing these key factors, the goal is to provide patients with a more effective and accessible option for pain management, reducing their reliance on healthcare facilities during painful episodes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease who experience acute pain crises.
Not a fit: Patients who do not have sickle cell disease or those who do not experience acute pain crises may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life for patients with sickle cell disease by providing an effective at-home treatment for pain crises.
How similar studies have performed: While the approach of using glycan-based therapeutics is innovative, similar strategies targeting pain management in sickle cell disease have shown promise, indicating potential for success.
Where this research is happening
San Carlos, UNITED STATES
- Ihp Therapeutics, INC. — San Carlos, United States (Active)
Researchers
- Principal investigator: John Paderi, John Paderi John Paderi — Ihp Therapeutics, INC.
- Study coordinator: John Paderi, John Paderi John Paderi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.